尽管内幕卖主和负面指标, Travere治疗技术达到了52周的高点。 Travere Therapeutics reached a 52-week high despite insider selling and negative metrics.

Travere治疗术(NASDAQ:TVTX)内幕人士一直在出售股票,William E. Rote和Roy D. Baynes最近进行了交易。 Travere Therapeutics (NASDAQ:TVTX) insiders have been selling shares, with recent transactions by William E. Rote and Roy D. Baynes. 股价增加势头,达到52周的高点,并获得积极的分析家评分,包括Wells Fargo提升为“超重”。 The stock has gained momentum, reaching a 52-week high and receiving positive analyst ratings, including a Wells Fargo upgrade to "overweight." 尽管财政指标不利,但机构投资有所增加,公司收入逐年增长69.6%,达到62.90亿美元。 Despite negative financial metrics, institutional investments have increased, and the company's revenue rose 69.6% year-over-year to $62.9M. Travere Therapeutics 专注于罕见肾脏和代谢疾病的治疗。 Travere Therapeutics focuses on therapies for rare kidney and metabolic diseases.